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What does this paper add to the literature? 
 
Surgical excision of lung metastases from colorectal cancer provides no Health Utility benefit 









Abstract (220 of 250 allowed)  
 
Aims: To assess the Health Utility of lung metastasectomy in the treatment of patients with 
colorectal cancer using the EQ-5D-3L questionnaire. 
 
Methods: Multidisciplinary colorectal cancer teams at 14 sites recruited patients to a 2-arm 
randomised controlled trial—Pulmonary Metastasectomy in Colorectal Cancer (PulMiCC). 
Remote randomisation was used, stratified by site and with minimisation for seven known 
confounders. Participants completed the EQ-5D-3L questionnaire together with other patient 
reported outcome measures at randomisation and then again at 3, 6, 12 and 24 months. These 
were returned by post to the co-ordinating centre. 
 
Results: Between December 2010 and December 2016, 93 participants were randomised 91 
of whom returned questionnaires. Survival and patient reported Quality of Life has been 
published previously, revealing no significant differences between the trial arms. Described 
here are patient reported data from the five dimensions of the EQ-5D-3L and the visual 
analogue scale (VAS) Health State. No significant difference was seen at any time point. The 
estimated difference between control and metastasectomy patients was  
-0.23 (95%CI-0.113,0.066) for the composite 0 to 1 index scale based on the descriptive 
system and 0.123(95%CI-7.24,7.49) for the 0 to 100 VAS scale. 
 
Conclusions: Following lung metastasectomy for colorectal cancer, no benefit was 
demonstrated for Health Utility, which alongside a lack of a survival or QoL benefit, calls 







Results of the Pulmonary Metastasectomy in Colorectal Cancer (PulMiCC) randomised 
controlled trial (RCT) showed no survival benefit from lung metastasasectomy for 
colorectal cancer (CRC).  Hence any  survival benefit that might be revealed by a much 
larger trial is likely to be far smaller than has generally been supposed.(1) Quality of 
Life(QoL) in PulMiCC included four Patient Reported Outcome Measures (PROMs):- the 
general and anaemia scale of Functional Assessment of Cancer Therapy (FACT-G-
An)(2), selected items from the Lung Cancer Brief Symptom Index (3) and the short 
form of the Spielberger State/Trait Anxiety Inventory (STAI)(4). These were chosen as 
the most relevant assessments for a thoracic oncological surgical intervention. No 
significant differences were found between the control and metastasectomy arms of the 
trial for any QoL outcomes and minimally important differences in these measures were 
largely ruled out.(5) 
 
In the absence of demonstrable benefit in either survival or QoL in PulMiCC, we 
examined the health utility of surgical removal of CRC lung metastases. Here we report 
analysis of data from the EQ-5D-3L questionnaire. This is a standardised health utility 
questionnaire, developed by the EuroQol Group, that provides a simple, generic 
measure of health for clinical and economic appraisal.(6) It is most often used in health 
economic studies to generate Quality Adjusted Life Years (QALYs)  The PulMiCC EQ-5D-
3L results reported here complement the trial survival data (1) [Fig.1] and will 




As full details of the RCT have been previously reported(1, 5) the trial design is 
provided only briefly. PulMiCC had two stages of consent:-Firstly following written 
informed consent, patients with lung metastases were registered for assessment. Those 
subsequently found to be eligible for metastasectomy, according to current practice, 
were invited to consent to randomisation, which was either to continued standard care 
(control), or metastasectomy. Sussex Health Outcomes Research & Education in Cancer 
(SHORE-C), University of Sussex, administered and coordinated all Patient Reported 
Outcome Measures (PROMs)  
 




Arm 1 Control. Patients were managed without metastasectomy, radiotherapy or image 
guided thermal ablation (IGTA).  
 
Arm 2 Pulmonary Metastasectomy (PM). The surgical approach (videothoracoscopy or 






Participants: Patients were eligible for inclusion if they had undergone resection of 
primary CRC with a prospect of cure, and had pulmonary metastasis confirmed at a 
multidisciplinary team (MDT) meeting. The discovery of the metastases could be 
synchronous or metachronous. In line with usual practice, there had to be no clinical 
indications of active colorectal cancer other than the known lung metastases. Prior liver 
resection for metastases did not preclude entry to the trial.  
 
Following consent to randomisation,  patients  were given the EQ-5D-3L 
questionnaire(7) at baseline. Subsequently, it was administered at 3, 6, 12 and 24 
months. The questionnaire asks patients to indicate on a visual analogue scale (VAS)  
their own health state ‘today’, between zero, worst imaginable health state, and 100, 
best imaginable health state, and to indicate their well-being in five dimensions (5D): 
mobility, self-care, usual activity, pain and discomfort, anxiety and depression as 1, 2 or 
3, the three levels (3-L) denoting no, some and extreme problems respectively. Country 
specific composite indices, on a scale of 0(worst) to 1(best), based on the five well-being 
scores have been developed. No index was found for Serbia so the United Kingdom (UK) 
index was calculated for all patients where the majority of trial centres were based. Of 
the randomised patients, 70% were in the UK, and Serbian patients were similarly 




To analyse the longitudinal EQ-5D-3L Health State and Index data, with adjustment for 
within-patient correlation, we used linear regression models with estimation using 
generalised estimating equations, using an independence working covariance 
assumption. The primary analysis estimated a common effect of metastasectomy over 
the follow-up times of 3, 6, 12 and 24 months, with adjustment for follow-up time, but 
variation of the treatment effect over time was examined. The potential impact of losses 




14 sites randomised 93 patients (Table 1): 47 to the control arm and 46 to 
metastasectomy.  No patient in the control group had a metastasectomy as their initial 
treatment; two had metastasectomy later at 14 and 17 months. Two patients declined 
the assigned metastasectomy. For this analysis they remain in their assigned groups. 
 
Of 93 randomised patients, one in each arm did not complete any EQ-5D-3L 
questionnaires, leaving 46 control and 45 metastasectomy patients.  
 







Summary tabulations of the 5 EQ-5D-3L well-being components are provided in Figure 
2. The three levels 1, 2 & 3 are colour coded with a traffic light convention, for each of 
the five dimensions, for every patient returning a form. The green ‘no problems’ area 
diminished at a similar rate in controls and metastasectomy patients. 
 
Figure 3 presents the EQ-5D-3L Index values, derived from the well-being components, 
over the 24 months of follow-up. The estimated effect, comparing metastasectomy with 
control, was -0.023, 95%CI:-0.113, 0.066, p=0.57. There was no evidence that the 
treatment difference varied over time (p=0.87, 3 df test). Reported minimally important 
differences for this measure in a UK population range from 0.10 to 0.12 suggesting there 
is no evidence of any important difference in the index values between the randomised 
groups.(9) 
 
Figure 4 Presents the EQ-5D-3L Health State scores over the 24 months of follow-up. 
The estimated effect, comparing metastectomy with control, was 0.125, 95%CI(-
7.24,7.49), p=0.97. There was no evidence that the treatment difference varied over 
time (p=0.87, 3 df test).  
 
Figure 5 presents the single dimension, self-reported Health State on a 1-100 scale with 









Data reported here from the EQ-5D-3L well-being dimensions and Health State show no 
differences between the randomised control and metastasectomy patients. This 
outcome is in line with the finding of no survival or QoL benefit in the PulMiCC RCT. (1, 
5) Lung metastasectomy is sometimes considered for psychological benefit but, as 
previously shown when using a comprehensive assessment of anxiety (STAI), no 
difference was evident in the Anxiety and Depression dimension of the EQ-5D-3L. The 
number of patients reporting ‘no problems’ in all the 5 dimensions of well-being 
diminished at a similar rate in controls (left) and metastasectomy patients.  
 
Evaluation of treatment of metastatic disease is a research priority for the Association 
of Coloproctology of Great Britain and Ireland (ACPGBI) (10) and is one of the targets in 
management of patients with colorectal cancer.  It is a treatment considered in the 
Improving Management of Patients with Advanced Colorectal Tumours, the IMPACT 
iniative of the Association of Coloproctologists of Great Britain and Ireland 
(ACPGBI).(11). Small effects cannot be ruled out by the findings of PulMiCC but they do 
not show a survival or QoL benefit from metastasectomy. (5) The additional study 
results reported here make it unlikely that there is a significant gain of health utility if 
patients are subjected to pulmonary metastasectomy. PulMiCC trial results may  help to 











Legends for Figures:  
 
Figure 1 
Survival in the PulMiCC trial to five years.  
 
Figure 2 
3-Level (3,2,1) scores in a traffic light convention, in the 5-Dimensions of well-being in 
the EuroQol: mobility, self-care, usual activity, pain and discomfort, anxiety and 
depression (EQ-5D-3L) at baseline, 3, 6, 12 and 24 months, in the control (Left) and 
metastasectomy arms. Each horizontal set of five represents a return from an individual 
patient. At each time point they are ranked by the unadjusted sum of the scores from 5 
at the top, to help visibility of the patterns between the arms and over time.  
 
Figure 3. EQ-5D-3L index scores in the two treatment arms. Arm 1: control and Arm 2: 
assigned to metastasectomy. Dashed lines are based on generalised estimating 
equations and solid lines on singular linear models that adjust for drop-out. 
 
Figure 4. EQ-5D-3L Health State scores in the two treatment arms. Arm 1: control and 
Arm 2: assigned to metastasectomy. Dashed lines are based on generalised estimating 
equations and solid lines on singular linear models that adjust for drop-out. 
 
 
Figure 5. The single dimension, self-reported Health State on a 1-100 scale with median 










































Table 1. Trial sites and number of patients returning any forms 
 
Site Returns 
Serbia, Institute for Lung Diseases of Vojvodina 28 
Sheffield, Northern General Hospital 16 
Basildon, Basildon Hospital 8 
Middlesbrough, James Cook Hospital 7 
Liverpool, Heart and Chest Hospital 7 
Burton, Queen’s Hospital 6 
Bristol, Royal Infirmary 5 
Manchester, The Christie Hospital 4 
London, Royal Free Hospital 3 
Plymouth, Derriford Hospital 2 
Wolverhampton, New Cross Hospital 2 
London, Royal Brompton Hospital 2 









Forms were sent at 3, 6, 12 and 24 months. 
 
Time point (months) 0 3 6 12 24 
Data available (n = 91 patients*) 83 84 82 72 60 
Percent return 91% 92% 90% 79% 66% 
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